Erratum: Germ cell tumors with malignant somatic transformation: A mayo clinic experience (Oncology Research and Treatment (2019) 42 (95-100) DOI: 10.1159/000495802)

The affiliations were incorrect. The correct affiliations are as follows: Caleb J. Scheckela, Heidi E. Kosiorekb, Richard Butterfieldb, Thai H. Hoc, Talal Hilalc aDepartment of Internal Medicine, Mayo Clinic, Scottsdale, AZ, USA; bDepartment of Health Sciences Research, BioStatistics, Mayo Clinic, Phoenix, AZ, USA; cDivision of Hematology/Oncology, Mayo Clinic, Phoenix, AZ, USA In the Abstract, wrong figures are given in the Results section. The correct Results section is as follows: Results: We identified 24 cases of GCTs with MST; the MST was adenocarcinoma in 50% and sarcoma in 50%. Median age at diagnosis was 27. Alpha-fetoprotein and beta-human chorionic gonadotropin were undetectable in 46%, both were elevated in 29%. The majority were advanced stage (71% stage III), and International Germ Cell Cancer Collaborative Group (IGCCCG) risk was classified as "good" in 58%. Median follow-up was 41 months (range 10-346 months). Median progression-free survival was 84 months (95% confidence interval (CI) 56-232), and median overall survival was 219 months (95% CI 165-not reported). Moreover, several figures in Patient Characteristics of the Results section were falsely given. The correct figures are as follows: Patient Characteristics The average age at diagnosis was 27 years (range 16-51 years) (Table 1). The types of MST were evenly distributed with 12 adenocarcinomas and 12 sarcomas, 5 of which were further subclassified as rhabdomyosarcoma. Primary tumor location was predominantly in the testes (21/24); a single case each arose from the mediastinum, pineal gland, and retroperitoneum (3/24). At the time of presentation, 4 patients had disease localized to the testes (stage I), 3 had disease metastasized to retroperitoneal lymph nodes (stage II), and the majority (17/24) of patients had stage III disease with metastatic locations including brain, neck, chest wall, lung, inferior vena cava, aorta, and bowel. IGCCCG risk classification identified most cases as "good risk" (14/24), and the rest as "intermediate risk" (4/24) and "poor risk" (6/24). Tumor marker analysis at diagnosis showed undetectable alpha-fetoprotein (AFP) and beta-human chorionic gonadotropin (β-hCG) in 46% (11/24), both were elevated in 29% (7/24), only AFP was elevated in 17% (4/24), and only β-hCG was elevated in 8% (2/24).